Introduction {#Sec1}
============

In Germany, breast cancer is the most frequently diagnosed cancer (31% of all cases), with women aged 70 or older at diagnosis representing 34% of these cases \[[@CR1], [@CR2]\]. In general, the risk of being diagnosed with breast cancer increases with age, affecting 1 in 48 women at age 45 and 1 in 28 women at age 65 \[[@CR1]\]. The number of elderly individuals in our population is growing rapidly. While 17% of the German population was aged 60 and older in 1960, this proportion increased to 27% in 2013 \[[@CR3]\]. Thus, the number of elderly patients with breast cancer continues to rise. Since elderly patients are more often affected by comorbidities or have an inferior general condition, the therapeutic options might need to be adjusted. As a woman aged 70 has a life expectancy of 16.8 years in Germany \[[@CR4]\], treatment decision should not be guided by the chronological age, but needs to balance the risks and benefits, health status, life expectancy, individual preferences and sustained quality of life.

Prognostic factors influencing breast cancer outcome relate to tumour and patient characteristics \[[@CR5]--[@CR7]\]; the interactions between these factors are complex and not yet fully understood. In comparison to younger patients, breast tumours in older women tend to have less aggressive profiles and lower recurrence rates \[[@CR8], [@CR9]\], but the relative survival in women older than 70 has been reported to be lower \[[@CR5], [@CR10], [@CR11]\]. Hampered by the underrepresentation of women aged ≥ 70 in clinical trials, there are only limited data on treatment of this group of patients \[[@CR12]--[@CR15]\]. Several reports have stated deviations from the guidelines in treatment of breast cancer in elderly patients, especially concerning surgery and adjuvant chemotherapy \[[@CR16]--[@CR19]\]. This so-called undertreatment might be due to missing clinical evidence as the standard treatment is based on recommendations extrapolated from younger patients participating in clinical trials \[[@CR14], [@CR20]\]. In addition, when assessing guideline conformity, factors preventing use of recommended treatments (such as comorbidities) are often missing. There is an urgent need for prospective clinical trials as well as population-based cohort studies tailored for elderly patients in order to optimise their treatment.

In this article, we present data on 2316 patients with breast cancer from the SENORA project within the TMK (Tumour Registry Breast Cancer). This prospective clinical cohort study recruits patients treated by office- and clinic-based medical oncologists, thus showing data from routine practice. We show patient and tumour characteristics as well as treatment details for the adjuvant and the palliative setting, both for younger patients and for patients aged ≥ 70. Furthermore, we present the disease-free survival (DFS) as well as the overall survival (OS) for both younger and elderly patients and additionally present a multivariate regression model identifying factors influencing the OS.

Patients and methods {#Sec2}
====================

Data source {#Sec3}
-----------

The TMK is an ongoing, open, longitudinal, multicentre, observational, prospective cohort study which started in 2007. The study was approved by the responsible ethics committee and is registered at ClinicalTrials.gov (NCT01351584). Eligible patients are women aged ≥ 18 years with histologically confirmed breast cancer, who received systemic antineoplastic treatment (endocrine therapy or chemotherapy). Written informed consent was obtained from all patients. Enrolment was restricted to patients who had signed informed consent no longer than 6 weeks after start of treatment, yet for the first 1000 patients with palliative treatment intention, the maximum span between start of first-line treatment and enrolment was 1 year. By project plan, patients were followed until death or for a maximum of 3 years. However, some sites provided update data on survival status after completion of the 3 year follow-up. The SENORA sub-project was set up in order to examine the treatment of elderly patients with breast cancer. 82 outpatient-centres and clinics for medical oncology located all over Germany actively recruited patients for the SENORA project between 2007 and 2011. The TMK has previously been described in detail \[[@CR21]\].

Cohort definition {#Sec4}
-----------------

Between 2007 and 2011, 2613 patients had been recruited into the TMK. 74 patients were excluded because of incomplete basic medical data or not fulfilling inclusion criteria. 21 patients who received trastuzumab monotherapy were excluded as the sample size was too small for a separate group. Of the remaining 2518 patients, 202 received neoadjuvant therapy but only 13 of them were aged 70 or older, therefore, this patient subgroup will not be discussed further. The present analysis focuses on 2316 patients receiving adjuvant or palliative first-line chemo- or endocrine therapy (Fig. [1](#Fig1){ref-type="fig"}). 1838 of the patients were younger than 70, 478 patients were aged ≥ 70. Outcome data including the OS are presented only for the prospectively enrolled patients, who had signed informed consent no longer than 6 weeks after the start of treatment to avoid overestimation of outcome (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Cohort definition. Number of patients enrolled in the TMK, split up according to the neoadjuvant, adjuvant or palliative treatment intention as well as to the age at start of therapy. Prospectively enrolled patients signed the informed consent no longer than 6 weeks after start of treatment

Statistical analysis {#Sec5}
--------------------

The aim of the SENORA project was the descriptive comparison of patient characteristics, treatment and outcome of elderly (age ≥ 70) versus younger patients. Time to events was analysed using Kaplan--Meier estimates. For the prospectively enrolled patients in adjuvant treatment intention, DFS was defined as the interval between start of adjuvant treatment and the date of recurrence or death from any cause. Patients lost to follow-up or without recurrence were censored at last contact. For the prospectively enrolled patients with palliative treatment intention, PFS was defined as the interval between start of first-line therapy and the date of first progression or death. Patients without such an event before start of second-line therapy were censored at either the start of second-line therapy or at last contact, whatever came first. OS was defined as the interval between start of first-line therapy and the date of death from any cause. Patients alive or lost to follow-up were censored at last contact. DSS was calculated from start of first-line therapy until date of death due to breast cancer. Patients alive, lost to follow-up or with other causes of death were censored at last contact or at date of death. The treatment duration was calculated using a Kaplan--Meier estimate and defined as time from start of treatment until end of treatment or death. If no end of therapy was documented, patients were censored at last contact/end of documentation. The median follow-up period was calculated using the reverse Kaplan--Meier estimate \[[@CR22]\]. All analyses were performed using IBM SPSS Statistics version 19.0 and SAS for Windows version 9.4. Exact binomial confidence intervals were calculated using *z*-test with StatSoft STATISTICA version 13.

For the prospectively enrolled patients with palliative treatment intention (maximum span of 6 weeks between start of treatment and signed informed consent), a Cox proportional hazards model was used to identify potential independent prognostic factors for survival. The following independent variables were examined for the model: age at start of first-line treatment, body mass index (BMI) at enrolment, Charlson comorbidity index, CCI \[[@CR23]\] at diagnosis, HR-status and HER2-status at diagnosis, stage and tumour grading at diagnosis as well as resection of the primary tumour. Furthermore, these treatment details at start of first-line therapy were included: prior neoadjuvant or adjuvant chemotherapy; number of metastatic sites and location of metastases. Nonvisceral metastases were defined as skin, bone or lymph node metastases. Confidence intervals (CI) for the regression coefficients were based on the Wald statistics. All presented *P* values are two-sided. 5% will be interpreted as significant. There were no adjustments to the level of significance.

Results {#Sec6}
=======

Patient and tumour characteristics in the adjuvant setting {#Sec7}
----------------------------------------------------------

Basic demographic and clinical data of the patients receiving adjuvant therapy are presented in Table [1](#Tab1){ref-type="table"}, comparing patients younger than 70 years to those aged ≥ 70. Median age at start of adjuvant therapy was 55 years (\< 70) compared to 73 years (≥ 70). The prevalence of comorbidities was higher for elderly (38% CCI ≥ 1) than for younger patients (18% CCI ≥ 1), with hypertension documented most frequently (57%). 35 (24%) of the elderly patients were ≥ 75 years old, 8 (6%) of them ≥ 80 years old. Regarding the receptor status, the two subgroups were comparable. Elderly patients more often presented with advanced tumour stage at diagnosis (26% stage III vs. 14% of the younger patients) and more often had lymph node involvement (58% vs. 48%).Table 1Patient and tumour characteristics in the adjuvant settingCharacteristic\< 70 (*n* = 996)≥ 70 (*n* = 144)MedianMin--MaxMedianMin--MaxAge at start of therapy, years55.121.6--69.972.870.0--85.5Characteristic*n*%*n*%BMI at enrolment^a^ Underweight50.510.7 Normal45445.64128.5 Overweight29429.55336.8 Obese22322.44430.6 Unknown202.053.5Patients with any comorbidity^b,c,e^47047.211881.9 Hypertension24024.18256.9 Diabetes mellitus696.9214.6 Cardiovascular disease343.41812.5Charlson comorbidity index^d^ CCI = 081481.78961.8 CCI ≥ 118218.35538.2Receptor status at diagnosis HR-positive, HER2-negative56957.18256.9 HR-positive, HER2-positive17617.71913.2 HR-negative, HER2-positive777.7106.9 Triple negative14714.82618.1 Unknown272.774.9Tumour stage at diagnosis I26826.92618.1 II44344.56041.7 III14114.23826.4 Unknown^f^14414.52013.9Tumour grading at diagnosis G1747.4117.6 G254054.26444.4 G337137.26545.1 GX111.142.8Node stage at diagnosis N050250.45840.3 N134134.24732.6 N2848.42215.3 N3565.61510.4 Unknown131.321.4*BMI* body mass index (kg/m^2^), *HR* hormone receptor, *HER2* human epidermal growth factor receptor 2, *Max* maximum, *Min* minimum^a^Underweight: BMI \< 18.5; normal: BMI 18.5 to \< 25, overweight: BMI 25 to \< 30, obese: BMI ≥ 30^b^At start of therapy^c^At least one comorbidity according to Charlson \[[@CR23]\] or additional concomitant diseases^d^Charlson Comorbidity Index (CCI) according to Quan et al. \[[@CR24]\]^e^Multiple answers provided^f^For some patients the exact stage could not be determined because of unknown parameters (TX, NX, MX)

Patient and tumour characteristics in the palliative setting {#Sec8}
------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} presents the basic characteristics of the two patient subgroups receiving palliative therapy. Median age at diagnosis was 53 versus 72 years, the BMI was similar. 75% of the elderly patients presented with comorbidities compared to 49% of the younger patients. 169 (51%) of the elderly patients were ≥ 75 years old, 66 (20%) of them ≥ 80 years old. 49% of the patients aged ≥ 70 had hypertension (vs. 29% of the younger patients) and 20% diabetes mellitus (vs. 7%). Generally, the prevalence of comorbidities was higher in elderly patients in palliative therapy (38% CCI ≥ 1 vs. 18% CCI ≥ 1). The distribution of receptor subtypes was comparable in younger and older patients. Independent of age, a similar number of patients presented with synchronous metastasis (30 vs. 29%), with nonvisceral (bone, skin and/or lymph node) metastases (36 vs. 37%) or with more than one metastatic site (42 vs. 40%). Referring to the location of the metastases, slightly more of the younger patients had brain metastases (3 vs. 1%), whereas slightly more elderly patients had metastases in the lung (7 vs. 10%). The proportion of patients with preceding adjuvant chemotherapy was a bit higher in the younger patient group (58% vs. 51%).Table 2Patient and tumour characteristics in the palliative settingCharacteristic\< 70 (*n* = 842)≥ 70 (*n* = 334)MedianMin--MaxMedianMin--MaxAge at diagnosis, years53.222.3--69.671.637.1--90.2Age at start of therapy, years59.122.5--70.075.170.0--92.8Characteristic*n*%*n*%BMI at enrolment^a^ Underweight70.861.8 Normal34440.912336.8 Overweight26231.111534.4 Obese17320.56018.0 Unknown566.7309.0Patients with comorbidity^d,e^41549.325074.9 Hypertension24128.616549.4 Diabetes mellitus556.56519.5 Cardiovascular disease202.43610.8 CCI = 0^f^68881.719257.5 CCI ≥ 115418.314242.5Receptor status at diagnosis HR-positive, HER2-negative38946.215947.6 HR-positive, HER2-positive16219.25416.2 HR-negative, HER2-positive789.3216.3 Triple negative9311.0288.4 Unknown12014.37221.6Tumour grading at diagnosis G1/242850.818354.8 G3/431437.311534.4 GX/Unknown10011.93610.8Resection of primary tumour R063675.525074.9 R1/2637.53510.5 RX/unknown14317.04914.7Metastasis at diagnosis No (metachronous, M0)48958.118455.1 Yes (synchronous, M1)24829.59729.0 MX^b^/Unknown10512.55315.9Location of metastases^d,g^ Visceral ± nonvisceral49458.719157.2 Nonvisceral only30235.912336.8 Unknown465.5206.0Bone only20724.68625.7Liver only769.0339.9Lung only566.7329.6Brain273.230.9Multiple and/or other location^c^43051.116047.9Unknown465.5206.0Number of metastatic sites^d^ = 144552.917953.6 \> 135141.713540.4 Unknown465.4206.0Preceding adjuvant therapy49058.217050.9*BMI* body mass index (kg/m^2^), *HR* hormone receptor, *HER2* human epidermal growth factor receptor 2, *Max* maximum, *Min* minimum^a^Underweight: BMI \< 18.5; normal: BMI 18.5 to \< 25, overweight: BMI 25 to \< 30, obese: BMI ≥ 30^b^MX, presence of distant metastasis was not evaluated or is not documented for the time of primary diagnosis^c^Other locations than the aforementioned or multiple locations^d^at start of palliative first-line therapy^e^At least one comorbidity according to Charlson \[[@CR23]\] or additional concomitant diseases^f^Charlson Comorbidity Index (CCI) according to Quan et al. \[[@CR24]\]^g^Nonvisceral: bone, lymph node and/or skin metastases

Treatment {#Sec9}
---------

Patients aged ≥ 70 at start of therapy less often underwent a breast conserving surgery (BCS) than younger patients (58%, 95% CI 49--66% vs. 72%, 95% CI 69--75%, Fig. [2](#Fig2){ref-type="fig"}a), and more often had a mastectomy (42%, 95% CI 34--50% vs. 25%, 95% CI 22--27%, Fig. [2](#Fig2){ref-type="fig"}b). After surgery, however, the same proportion of patients in both subgroups received radiotherapy, 81--85% after BCS and 55% after mastectomy (Fig. [2](#Fig2){ref-type="fig"}a, b). The proportion of taxane-based chemotherapy was similar independent of the age in the adjuvant setting (61 vs. 62%), while fewer elderly patients received this regimen in palliative first-line (29%, 95% CI 23--37% vs. 36%, 95% CI 32--40%, Fig. [2](#Fig2){ref-type="fig"}c). For patients with HER2-positive tumours, administration of anti-HER2-therapy in the adjuvant and palliative first-line setting was similar between the age groups (Fig. [2](#Fig2){ref-type="fig"}d). A higher proportion of elderly patients with HR-positive tumours received endocrine therapy only, 18% (95% CI 11--27%) versus 6% (95% CI 5--8%) in the adjuvant and 53% (95% CI 46--60%) versus 41% (95% CI 37--45%) in the palliative setting (Fig. [2](#Fig2){ref-type="fig"}e).Fig. 2Treatment of breast cancer for patients aged \< 70 in comparison to patients aged ≥ 70. **a** Proportion of patients receiving breast conserving surgery (BCS) in the adjuvant treatment setting. The proportion of patients receiving radiotherapy (RT) is calculated for all patients receiving BCS. **b** Proportion of patients receiving mastectomy (Mx) in the adjuvant treatment setting. The proportion of patients receiving radiotherapy is calculated for all patients receiving Mx. **c** Proportion of patients receiving taxane-based chemotherapy (of all patients receiving chemotherapy). **d** Proportion of patients receiving anti-HER2-therapy (of all patients with HER2-positive tumours). **e** Proportion of patients with HR-positive tumours receiving systemic chemotherapy and/or endocrine therapy. In the adjuvant treatment setting, patients receiving chemotherapy and endocrine therapy as well as patients receiving only chemotherapy were added up. 114 younger patients (15.3%) and 12 elderly patients (11.9%) received chemotherapy without endocrine therapy. Error bars represent the 95% confidence interval (CI) Abbreviations: *BCS* breast conserving surgery, *CI* confidence interval, *CTx* chemotherapy, *ET* endocrine therapy, *HER2* human epidermal growth factor receptor 2, *HR* hormone receptor, *Mx* mastectomy, *pos* positive, *pts* patients, *RT* radiotherapy

Treatment response and outcome data {#Sec10}
-----------------------------------

For all prospectively enrolled patients (see Fig. [1](#Fig1){ref-type="fig"}), response rates and outcome data according to the different treatment regimens are shown in Table [3](#Tab3){ref-type="table"}. The median follow-up period was 41.3 months (range 33--53 months) for all patients, with only a slight difference between the age groups: 42.8 months (range 33--54 months) vs. 37.9 months (range 29--47 months) for patients aged ≥ 70.Table 3Outcome data in the adjuvant and palliative settingAdjuvant setting (prospectively enrolled patients)\< 70 (*n* = 951)≥ 70 (*n* = 139)Patients receiving chemotherapy (*n*, %)71475.1%9266.2% Number of cycles (median, min--max)^a^6.03.0--6.04.03.0--6.0 Duration of CTx in months (median, 95% CI)^b^3.5NA--NA3.53.5--3.6 End of CTx documented^c^ (*n*, %)70999.3%9198.9%Patients receiving targeted therapy (*n*, %)19220.2%2820.1% Number of cycles (median, range)^d^17.013.0--18.01812.0--18.0 Duration of TT in months (median, 95% CI)14.714.2--15.615.211.7--16.6 End of TT documented^c^ (*n*, %)18998.4%2796.4%Patients receiving endocrine therapy (*n*,  %)61564.7%9064.7% Duration of ET in months (median, 95% CI)59.558.5--61.959.243.2--NA End of ET documented^c^ (*n*, %)15925.9%2527.8%Disease-free survival---all patients and treatments951100%139100% Events (*n*, %)11011.6%1913.7% Median DFSNANA Survival rate (%, 95% CI)  12 months96.3%94.8--97.394.0%88.3--97.0  24 months91.4%89.2--93.190.2%83.4--94.4  36 months87.8%85.3--89.985.5%77.1--91.0Palliative first-line setting (prospectively enrolled patients)\< 70 (*n* = 554)≥ 70 (*n* = 239)Patients receiving endocrine therapy (*n*, %)13223.8%8535.6% Duration of ET in months (median, 95% CI)15.913.3--20.215.410.9--20.1Best response CR/PR2619.7%1214.1% SD4634.8%2731.8% PD2418.2%1922.4% Missing3627.3%2731.8%Patients receiving chemotherapy (*n*, %)42276.2%15464.4% Duration of CTx^a^ in months (median, 95% CI)5.14.6--5.83.83.5--4.9Best response CR/PR17341.0%5233.8% SD11527.3%4126.6% PD6615.6%3422.1% Missing6816.1%2717.5%Progression-free survival42075.8%15263.6% Events (*n*, %)23756.2%10266.2% Median PFS (months, 95% CI)12.210.8--13.37.66.6--8.9Overall survival---all patients and treatments554100%239100% Events (*n*, %)27549.6%14661.1% Median OS (months, 95% CI)39.734.9--44.224.919.9--30.1 Survival rate (%, 95% CI)  12 months83.8%80.4--86.771.6%65.3--77.0  24 months68.2%63.9--72.151.6%44.7--58.0  36 months53.5%48.8--57.937.8%31.0--44.5Duration of therapy was calculated with a Kaplan--Meier estimate*CI* confidence interval, *CR* complete response, *CTx* chemotherapy, *ET* endocrine therapy; NA, not available (not reached); OS, overall survival, *PD* progressive disease, *PFS* progression-free survival, *PR* partial response, *SD* stable disease, *StD* standard deviation, *TT* targeted therapy^a^For all patients with available data on this parameter: \< 70, *n* = 708; ≥ 70, *n* = 91^b^Without targeted therapy (TT)^c^Patients who completed the respective treatment within the follow-up period of this cohort study. Percentages refer to all patients receiving the respective treatment^d^For all patients with available data on this parameter: \< 70, *n* = 179; ≥ 70, *n* = 25

In the adjuvant setting, duration of chemotherapy did not differ between younger and elderly patients. The DFS rates were comparable: 88% of the younger patients lived at least 36 months without recurrence compared to 86% of the patients aged ≥ 70 (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}a).Fig. 3Survival of patients aged \< 70 compared to patients aged ≥ 70. Survival analysis for the prospectively enrolled patients (see Fig. 1). **a** DFS for the patients with (neo)adjuvant treatment intention, **b** OS for the patients with palliative treatment intention, **c** Disease-specific survival for the patients in the palliative setting. Abbreviations: *CCI* Charlson Comorbidity Index, *CI* confidence interval, *DFS* disease-free survival; *DSS* disease-specific survival, *OS* overall survival

In the palliative first-line setting, duration of endocrine therapy in patients with HR-positive tumours was comparable (15.9 months, 95% CI 13.3--20.2 vs. 15.4 months, 95% CI 10.9--20.1). Endocrine therapy was successful in 55% younger and 46% elderly patients, as assessed by the disease control rate (DCR), covering complete/partial response and stable disease (CR/PR and SD; Table [3](#Tab3){ref-type="table"}). Chemotherapy was successful in 68% of the younger and 60% of the elderly patients (DCR, Table [3](#Tab3){ref-type="table"}). The median PFS was 12.2 months (95% CI 10.8--13.3) for the younger and 7.6 months (95% CI 6.6--8.9) for the elderly patients treated with chemotherapy. The OS analysis, calculated from start of first-line therapy, revealed that patients aged ≥ 70 had a significantly shorter median OS of 24.9 months (95% CI 20.0--30.2) compared to 39.7 months (95% CI 34.9--44.2) for younger patients (Fig. [3](#Fig3){ref-type="fig"}b). Breast cancer was documented as cause of death for 85% of the younger patients and for 73% of the patients aged ≥ 70. Median disease-specific survival was 46.3 months (95% CI 40.2--54.2) for younger and 35.3 (95% CI 25.5--40.5) months for elderly patients (Fig. [3](#Fig3){ref-type="fig"}c).

Factors influencing overall survival {#Sec11}
------------------------------------

A multivariate regression analysis showed that not only an age of ≥ 70 at start of palliative first-line therapy, but also negative HR- and HER2-status, higher number of metastatic sites, higher CCI and high tumour grading at diagnosis were associated with a significantly increased risk of overall mortality (Fig. [4](#Fig4){ref-type="fig"}). In contrast, nonvisceral metastases (vs. visceral metastases), metastasis at diagnosis (synchronous (M1) vs. metachronous (M0)) as well as obesity (obese vs. normal) were associated with a decreased risk of mortality (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Multivariate regression analysis. Cox proportional hazards model for overall survival. Bold writing: significant results (*p* \< 0.05). \*Metastasis at diagnosis was documented either synchronous (M1) or metachronous (M0). Abbreviations: *BMI* body mass index, *CCI* Charlson Comorbidity Index, *CI* confidence interval, *HR* hazard ratio, *HER2* human epidermal growth factor receptor 2, *metachr* metachronous, *synchr* synchronous

Discussion {#Sec12}
==========

The proportion of elderly patients with breast cancer is growing continuously. Treatment decisions should not be based on chronological age alone, but need to ensure that elderly patients get the best quality of care. We shed light on the medical management of patients aged ≥ 70 in routine care, presenting data on treatment and outcome of 478 elderly and 1838 younger patients. In the adjuvant setting, elderly patients less often received chemotherapy. The 3-year DFS was similar to that of younger patients. In the palliative setting, the median OS of elderly patients was significantly shorter than that of younger patients, despite similar treatment. However, not only the age at start of therapy, but also the presence of comorbidities or metastases, negative HR- or HER2-status or high tumour grading at diagnosis significantly increased the risk of mortality.

This study is limited by the sole enrolment of patients receiving systemic therapy, potentially excluding patients refusing such treatment as well as very frail older patients not able to receive systemic therapy. The interpretation of data from cohort studies is limited by the lack of randomization which has to be considered when comparing outcome data between subgroups. In the TMK registry, there are no specifications as to the timing, frequency or criteria of tumour assessment and, thus DFS and PFS data should be considered as the best clinical approximation and might not be identical to the PFS determined in clinical trials. Strengths of this study are the prospective, longitudinal design and the participation of oncologists all over Germany.

At what chronological age is a patient defined as 'elderly'? Even this simple question raises multiple issues and complicates comparisons between studies. Some authors set the threshold at ≥ 65 years \[[@CR13]\], others at ≥ 70 \[[@CR10], [@CR11], [@CR25]\] or even at ≥ 80 years \[[@CR26]\]. The NCCN task force report on breast cancer in the older woman recommended the cutoff point '70 years or older', as there is almost no clinical evidence for treatment of this patient subgroup \[[@CR14]\], rendering prospective cohort studies like ours important information resources on the patients aged ≥ 70.

Poor diagnostic assessment, one of the factors for substandard treatment, was not observed in the SENORA cohort. The proportion of adjuvant patients with unknown/undocumented receptor status, tumour or nodal stage was similar in both age groups. It has been shown that patients aged ≥ 55 often have a more advanced disease at diagnosis, yet slower proliferation rates and less aggressive tumour profiles, including a higher proportion of HR-positive tumours \[[@CR8]\]. Consistent with these reports, 26% of the elderly patients in the SENORA cohort were initially diagnosed with tumour stage III compared to 14% of the younger patients. The finding that patients aged \> 70 more frequently present with more advanced tumours might be a consequence of recommendations for screening mammograms, which have only been established for the age groups between 50 and 70 years \[[@CR27]\]. The HR-positive tumours, however, were equally distributed over the age groups. Although no differences in tolerance of BCS or mastectomy have been shown due to age \[[@CR28]\], elderly patients are more often treated with mastectomy \[[@CR13]\]. Indeed, our results show that 42% of the elderly patients underwent mastectomy, compared to 24% of the younger women. This tendency is in concordance with the NORA cohort study showing that 49% of the patients aged ≥ 70 versus 40% of the patients aged 65--69 were treated with mastectomy \[[@CR13]\]. The value of adjuvant chemotherapy in the elderly population is controversial (reviewed in 30) and it has been reported that few elderly patients who are candidates for chemotherapy actually receive it \[[@CR19], [@CR29]\]. Of the prospectively enrolled patients with adjuvant treatment intention, 75% of the younger and 66% of the elderly patients received adjuvant chemotherapy, although the proportion of patients with more advanced tumour stages was higher in the elderly group. Interestingly, the 3-year DFS rate was similar between both groups and comparable to previously published data \[[@CR30]\]. The number of cycles and duration of treatment was similar between the age groups. In short, 'substandard treatment' of elderly patients was not observed in our setting.

For the patients aged ≥ 70 with palliative treatment intention, median OS was significantly shorter than that of the younger patients (24.9 compared to 39.7 months). This difference was markedly reduced in the DSS, implicating that not only the breast cancer, but also other factors influence the survival of elderly patients. Indeed, a Cox proportional hazards model showed that not only higher age at diagnosis, but also comorbidities, a higher number of metastatic sites, high tumour grading or negative HR- or HER2-status increased the risk of mortality. These results are in concordance with the literature about prognostic factors in metastatic breast cancer \[[@CR7], [@CR31]--[@CR33]\]. Interestingly, obesity (BMI ≥ 30) was associated with a decreased risk of mortality, the opposite of what was shown previously \[[@CR34]\]. Synchronous metastasis at diagnosis was also favourable, a fact that could be attributed to the missing previous adjuvant chemotherapy, which has been identified as predicting factor negatively influencing survival \[[@CR7], [@CR35], [@CR36]\]. Thus, the assessment of treatment and outcome of elderly patients should consider that factors other than age also affect decision making and prognosis.

Conclusions {#Sec13}
===========

The results from the SENORA project add valuable information to the ongoing debate about 'undertreatment' of elderly patients---there was no substantial difference in the treatment of elderly women with breast cancer in German routine care. Age was but one of various prognostic factors influencing the survival of elderly patients and---despite similar treatment---the overall survival of patients aged ≥ 70 was shorter.
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